Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients

First Posted Date
2022-10-27
Last Posted Date
2022-11-28
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
50
Registration Number
NCT05596890
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery

First Posted Date
2022-10-26
Last Posted Date
2024-05-06
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
36
Registration Number
NCT05594290
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

First Posted Date
2022-10-20
Last Posted Date
2023-11-28
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
418
Registration Number
NCT05587374
Locations
🇨🇳

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China

and more 16 locations

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

First Posted Date
2022-10-13
Last Posted Date
2024-12-18
Lead Sponsor
BeiGene
Target Recruit Count
121
Registration Number
NCT05577702
Locations
🇨🇳

Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, China

🇨🇳

The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

and more 11 locations

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

First Posted Date
2022-10-12
Last Posted Date
2023-11-22
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
460
Registration Number
NCT05576272
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangzhou, China

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

First Posted Date
2022-10-06
Last Posted Date
2024-07-11
Lead Sponsor
Kortuc, Inc.
Target Recruit Count
70
Registration Number
NCT05570422
Locations
🇹🇭

Site 4, Chiang Mai, Thailand

🇮🇳

Site 1, Visakhapatnam, India

🇹🇭

Site 5, Bangkok, Thailand

and more 2 locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

First Posted Date
2022-09-27
Last Posted Date
2024-11-12
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
1170
Registration Number
NCT05555732
Locations
🇺🇸

Florida Cancer Specialists-North, Saint Petersburg, Florida, United States

🇯🇵

Osaka International Cancer Institute, Osaka, Japan

🇺🇸

Southern Cancer Center Pc, Daphne, Alabama, United States

and more 206 locations

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

First Posted Date
2022-09-15
Last Posted Date
2024-08-29
Lead Sponsor
Mayo Clinic
Target Recruit Count
320
Registration Number
NCT05541016
Locations
🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

First Posted Date
2022-09-10
Last Posted Date
2024-10-29
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
120
Registration Number
NCT05535166
Locations
🇺🇸

Primary Children's Hospital, Salt Lake City, Utah, United States

🇺🇸

Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States

🇺🇸

Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States

and more 7 locations

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

First Posted Date
2022-09-02
Last Posted Date
2023-05-03
Lead Sponsor
Wei Jiang
Target Recruit Count
440
Registration Number
NCT05527470
Locations
🇨🇳

Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China

🇨🇳

Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy